TKA: Wound infiltration with DepoFoam bupivacaine is an effective postoperative analgesia .
This report has been verified
by one or more authors of the
original publication.
A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty
Knee. 2012 Oct;19(5):530-6. doi: 10.1016/j.knee.2011.12.004. Epub 2012 Jan 28144 patients who were undergoing primary unilateral total knee arthroplasty (TKA) were randomized to receive wound infiltration with DepoFoam bupivacaine (133 mg, 266 mg, 399 mg or 532 mg) or bupivacaine HCl with epinephrine. Over 5 days, the DepoFoam bupivacaine groups had significantly lower pain scores at rest than the bupivacaine HCl group at several time periods. On day 5, the cumulative pain score at rest was significantly lower in the DepoFoam 532 mg group than in the bupivacaine HCl group. On day 8, the blinded care provider was also significantly more satisfied with the DepoFoam 532 mg group than with the bupivacaine HCl group. There were no other significant differences between the groups.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
